Manifestaciones psiquiátricas asociadas a trastornos neuroendocrinos: artículo de revisión
DOI:
https://doi.org/10.18041/1900-7841/rcslibre.2021v16n2.7390Palabras clave:
Neuroendocrino, Manifestaciones psiquiátricas, Psiquiatría de enlaceResumen
El comportamiento humano y las enfermedades mentales se ven estrechamente influenciados por el funcionamiento del sistema endocrino y el entendimiento de esta relación se ha podido construir a partir de estudio de la Neurociencia. Una gran cantidad de personas con trastornos neuroendocrinos presentan manifestaciones psiquiátricas y estas pueden incluso anteceder al diagnóstico del trastorno neuroendocrino. Estas manifestaciones disminuyen de cierta medida al instaurarse el manejo del trastorno, pero en algunas ocasiones, requieren manejo psicoterapéutico o farmacológico específico. Este artículo de revisión pretende informar y sensibilizar al lector sobre el porqué de esta frecuente asociación; ilustra las presentaciones clínicas más habituales y postula algunas estrategias terapéuticas. Los trastornos neuroendocrinos a tratar son: el hipotiroidismo, hipertiroidismo, hipoparatiroidismo, hiperparatiroidismo, síndrome de Cushing, enfermedad de Addison, hiperprolactinemia, trastorno dismórfico premenstrual, hiperandrogenismo de origen ovárico, e hipogonadismo. Es importante también enfatizar que el correcto manejo de estos pacientes requerirá de la participación de un grupo interdisciplinario.
Descargas
Referencias
Orozco-Cabal L, Pollandt S, Liu J, Shinnick-Gallagher P, Gallagher JP. Regulation of synaptic transmission by CRF receptors. Rev Neurosci. 2006;17(3):279-307.
Gallagher JP, Orozco-Cabal LF, Liu J, Shinnick-Gallagher P. Synaptic physiology of central CRH system. Eur J Pharmacol. 2008;583(2-3):215-225.
Liu J, Yu B, Orozco-Cabal L, et al. Chronic cocaine administration switches corticotropin-releasing factor2 receptor-mediated depression to facilitation of glutamatergic transmission in the lateral septum. J Neurosci. 2005;25(3):577-583.
Feldman AZ, Shrestha RT, Hennessey JV. Neuropsychiatric manifestations of thyroid disease. Endocrinol Metab Clin North Am. 2013;42(3):453-476.
Stathatos N. Thyroid physiology. Med Clin North Am. 2012;96(2):165-173.
Bauer M, Goetz T, Glenn T, Whybrow PC. The thyroid-brain interaction in thyroid disorders and mood disorders. J Neuroendocrinol. 2008;20(10):1101-1114.
Waring AC, Arnold AM, Newman AB, Bùzková P, Hirsch C, Cappola AR. Longitudinal changes in thyroid function in the oldest old and survival: the cardiovascular health study all-stars study. J Clin Endocrinol Metab. 2012;97(11):3944-3950.
Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf). 1995;43(1):55-68.
Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Spencer D, Fava M. The STAR*D study: treating depression in the real world. Cleve Clin J Med. 2008;75(1):57-66.
McIntyre RS, Filteau MJ, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2014;156:1-7.
Tan ZS, Beiser A, Vasan RS, et al. Thyroid function and the risk of Alzheimer disease: the Framingham Study. Arch Intern Med. 2008;168(14):1514-1520.
Bommer M, Eversmann T, Pickardt R, Leonhardt A, Naber D. Psychopathological and neuropsychological symptoms in patients with subclinical and remitted hyperthyroidism. Klin Wochenschr. 1990;68(11):552-558.
Sait Gönen M, Kisakol G, Savas Cilli A, et al. Assessment of anxiety in subclinical thyroid disorders. Endocr J. 2004;51(3):311-315.
Vita R, Lapa D, Trimarchi F, Benvenga S. Stress triggers the onset and the recurrences of hyperthyroidism in patients with Graves' disease. Endocrine. 2015;48(1):254-263.
Johnston AM, Eagles JM. Lithium-associated clinical hypothyroidism. Prevalence and risk factors. Br J Psychiatry. 1999;175:336-339.
Kibirige D, Luzinda K, Ssekitoleko R. Spectrum of lithium induced thyroid abnormalities: a current perspective. Thyroid Res. 2013;6(1):3.
Sierra P, Cámara R, Tobella H, Livianos L. What is the real significance and management of major thyroid disorders in bipolar patients? Rev Psiquiatr Salud Ment. 2014;7(2):88-95.
Bogazzi F, Bartalena L, Brogioni S, et al. Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab. 1999;84(2):499-503.
Geffken GR, Ward HE, Staab JP, Carmichael SL, Evans DL. Psychiatric morbidity in endocrine disorders. Psychiatr Clin North Am. 1998;21(2):473-489
Kamboj MK, Tareen RS. Management of nonpsychiatric medical conditions presenting with psychiatric manifestations. Pediatr Clin North Am. 2011;58(1):219-41
Valera Besard B, Soria Dorado MA, Piédrola Maroto G, Hidalgo Tenorio MC. Manifestaciones psiquiátricas secundarias a las princiales enfermedades endocrinológicas. An. Med Interna. 2003;20:206-12.
Altay H, Zorlu A, Kocum HT, Demircan S, Yilmaz N, Yilmaz MB. Relationship between parathyroid hormone and depression in heart failure. Arq Bras Cardiol. 2012;99(4):915-923.
Mampalam TJ, Tyrrell JB, Wilson CB. Transsphenoidal microsurgery for Cushing disease. A report of 216 cases. Ann Intern Med. 1988;109(6):487-493.
Bratek A, Koźmin-Burzyńska A, Górniak E, Krysta K. Psychiatric disorders associated with Cushing's syndrome. Psychiatr Danub. 2015;27 Suppl 1:S339-S343.
Kelly WF. Psychiatric aspects of Cushing's syndrome. QJM. 1996;89(7):543-551.
Sonino N, Fallo F, Fava GA. Psychosomatic aspects of Cushing's syndrome. Rev Endocr Metab Disord. 2010;11(2):95-104.
Starkman MN, Giordani B, Gebarski SS, Berent S, Schork MA, Schteingart DE. Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease. Biol Psychiatry. 1999;46(12):1595-1602.
Loosen PT, Chambliss B, DeBold CR, Shelton R, Orth DN. Psychiatric phenomenology in Cushing's disease. Pharmacopsychiatry. 1992;25(4):192-198.
Ryan MC, Sharifi N, Condren R, Thakore JH. Evidence of basal pituitary-adrenal overactivity in first episode, drug naïve patients with schizophrenia. Psychoneuroendocrinology. 2004;29(8):1065-1070.
Lorentzen R, Kjær JN, Østergaard SD, Madsen MM. Thyroid hormone treatment in the management of treatment-resistant unipolar depression: a systematic review and meta-analysis. Acta Psychiatr Scand. 2020;141(4):316-326.
MacMaster FP, El-Sheikh R, Upadhyaya AR, Nutche J, Rosenberg DR, Keshavan M. Effect of antipsychotics on pituitary gland volume in treatment-naïve first-episode schizophrenia: a pilot study. Schizophr Res. 2007;92(1-3):207-210.
Walker E, Mittal V, Tessner K. Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annu Rev Clin Psychol. 2008;4:189-216.
Fitzgerald P, Dinan TG. Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol. 2008;22(2 Suppl):12-19.
Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80(4):1523-1631.
Bernard V, Young J, Chanson P, Binart N. New insights in prolactin: pathological implications. Nat Rev Endocrinol. 2015;11(5):265-275.
Perry BI, Goldring KJ, Menon SJ. Prolactin monitoring in the acute psychiatry setting. Psychiatry Res. 2016;235:104-109.
Nicholas L, Dawkins K, Golden RN. Psychoneuroendocrinology of depression. Prolactin. Psychiatr Clin North Am. 1998;21(2):341-358.
Ajmal A, Joffe H, Nachtigall LB. Psychotropic-induced hyperprolactinemia: a clinical review. Psychosomatics. 2014;55(1):29-36.
Glezer A, Bronstein MD. Prolactinomas. Endocrinol Metab Clin North Am. 2015;44(1):71-78.
Molitch ME. Drugs and prolactin. Pituitary. 2008;11(2):209-218.
Oviedo GF, Gómez Restrepo C, Bohórquez Peñaranda A, et al. Evaluación y seguimiento metabólico del paciente con diagnóstico de esquizofrenia [Metabolic Control, Evaluation and Follow-up Interventions in Patients With Schizophrenia]. Rev Colomb Psiquiatr. 2015;44(4):220-229.
Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry. 2004;65(12):1607-1761.
Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962.
Nussbaum AM, Stroup TS. Paliperidone for treatment of schizophrenia. Schizophr Bull. 2008;34(3):419-422.
Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003;166(4):391-399.
Rubinow DR, Schmidt PJ. Gonadal steroid regulation of mood: the lessons of premenstrual syndrome. Front Neuroendocrinol. 2006;27(2):210-216.
Rubinow DR, Schmidt PJ, Roca CA. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry. 1998;44(9):839-850.
Freeman EW. Current update of hormonal and psychotropic drug treatment of premenstrual dysphoric disorder. Curr Psychiatry Rep. 2002;4(6):435-440.
Avis NE, McKinlay SM. The Massachusetts Women's Health Study: an epidemiologic investigation of the menopause. J Am Med Womens Assoc (1972). 1995;50(2):45-63
Schmidt PJ. Mood, depression, and reproductive hormones in the menopausal transition. Am J Med. 2005;118 Suppl 12B:54-58.
Schmidt PJ, Murphy JH, Haq N, Danaceau MA, St Clair L. Basal plasma hormone levels in depressed perimenopausal women. Psychoneuroendocrinology. 2002;27(8):907-920.
Wariso BA, Guerrieri GM, Thompson K, et al. Depression during the menopause transition: impact on quality of life, social adjustment, and disability. Arch Womens Ment Health. 2017;20(2):273-282
McCartney CR, Marshall JC. CLINICAL PRACTICE. Polycystic Ovary Syndrome. N Engl J Med. 2016;375(1):54-64.
Rodriguez-Paris D, Remlinger-Molenda A, Kurzawa R, et al. Psychiatric disorders in women with polycystic ovary syndrome. Psychiatr Pol. 2019;53(4):955-966.
Rasgon NL, Altshuler LL, Gudeman D, et al. Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report. J Clin Psychiatry. 2000;61(3):173-178.
Scaruffi E, Gambineri A, Cattaneo S, Turra J, Vettor R, Mioni R. Personality and psychiatric disorders in women affected by polycystic ovary syndrome. Front Endocrinol (Lausanne). 2014;5:185.
Ebinger M, Sievers C, Ivan D, Schneider HJ, Stalla GK. Is there a neuroendocrinological rationale for testosterone as a therapeutic option in depression?. J Psychopharmacol. 2009;23(7):841-853.
Almeida OP, Waterreus A, Spry N, Flicker L, Martins RN. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology. 2004;29(8):1071-1081.
Virkkunen M, Rawlings R, Tokola R, et al. CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers. Arch Gen Psychiatry. 1994;51(1):20-27.
Sher L, Grunebaum MF, Sullivan GM, et al. Testosterone levels in suicide attempters with bipolar disorder. J Psychiatr Res. 2012;46(10):1267-1271.
Schneider HJ, Pagotto U, Stalla GK. Central effects of the somatotropic system. Eur J Endocrinol. 2003;149(5):377-392.
Sievers C, Dimopoulou C, Pfister H, et al. Prevalence of mental disorders in acromegaly: a cross-sectional study in 81 acromegalic patients. Clin Endocrinol (Oxf). 2009;71(5):691-701.
Tiemensma J, Biermasz NR, van der Mast RC, et al. Increased psychopathology and maladaptive personality traits, but normal cognitive functioning, in patients after long-term cure of acromegaly. J Clin Endocrinol Metab. 2010;95(12):E392-E402.
Hugenholtz GW, Heerdink ER, van Staa TP, Nolen WA, Egberts AC. Risk of hip/femur fractures in patients using antipsychotics. Bone. 2005;37(6):864-870
Howard L, Kirkwood G, Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry. 2007;190:129-134.
Stewart DE, Boydell KM. Psychologic distress during menopause: associations across the reproductive life cycle. Int J Psychiatry Med. 1993;23(2):157-162.
McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev. 1999;20(3):279-307.
Athanasoulia-Kaspar AP, Popp KH, Stalla GK. Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist. Endocr Connect. 2018;7(2):R88-R94.
Penninx BWJH, Lange SMM. Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dialogues Clin Neurosci. 2018;20(1):63-73.
Tost M, Monreal JA, Armario A, et al. Targeting Hormones for Improving Cognition in Major Mood Disorders and Schizophrenia: Thyroid Hormones and Prolactin. Clin Drug Investig. 2020;40(1):1-14.
Sánchez-González R, Monteagudo-Gimeno E, Rodríguez-Urrutia A, et al. Psychotic disorders versus other psychiatric diagnoses in consultation-liaison psychiatry: 10 years of a single-center experience. Actas Esp Psiquiatr. 2019;47(4):149-157.
